ANI's Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug Tranxene.
The current annual US market for Clorazepate Dipotassium Tablets is approximately USD 25.8m, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
ANI Pharmaceuticals is engaged in developing, manufacturing, and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.
Its team is focused on delivering sustainable growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging its North American manufacturing capabilities.
Accord Healthcare introduces Pemetrexed Lyo. Injection to range of chemotherapy drugs
Astellas receives unfavourable decision in LEXISCAN(R) 0.4mg/mL US patent trial
Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows
UK Grants Licence for Teva's Ophthalmology Biosimilar Ongavia
Aztiq allies with Innobic to complete USD500m transaction to create international pharma powerhouse
Alcami partners with Civica Inc
Fresenius Kabi Launches New Generic for the Treatment of Multiple Myeloma